New hope for hard-to-treat ovarian cancer: experimental combo enters phase 2 trial
NCT ID NCT06434610
First seen May 06, 2026 · Last updated May 06, 2026
Summary
This study tests whether adding the experimental drug B013 to standard chemotherapy (paclitaxel) can help people with ovarian, fallopian tube, or primary peritoneal cancer that has stopped responding to platinum-based treatments. About 90 participants will receive either the combination or a placebo plus paclitaxel. The main goal is to see if the combination delays cancer growth or improves survival.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PLATINUM-RESISTANT RECURRENT OVARIAN CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Beijing Cancer Hospital
RECRUITINGBeijing, China
Contact
-
Cancer Hospital of Shandong First Medical University
RECRUITINGJinan, China
Contact
-
Fudan University Shanghai Cancer center
RECRUITINGShanghai, China
Contact
-
Fujian Cancer Hospital
RECRUITINGFuzhou, China
Contact
-
Guangxi Medical University Cancer Hospital
RECRUITINGNanning, China
Contact
-
Henan Cancer Hospital
RECRUITINGZhengzhou, China
Contact
-
Qilu Hospital of Shandong University
RECRUITINGJinan, China
Contact
-
Shananxi Provincial Cancer Hospital
RECRUITINGXi'an, China
Contact
-
Sun Yat-sen Memorial Hospital, Sun Yat-sen University
RECRUITINGGuangzhou, China
Contact
-
The First Affiliated Hospital of Bengbu Medical University
RECRUITINGBengbu, China
Contact
-
The First Affiliated Hospital of Xiamen University
RECRUITINGXiamen, China
Contact
-
The Obstetrics & Gynecology Hospital of Fudan University
RECRUITINGShanghai, China
Contact
-
The Second Hospital of Hebei Medical University
RECRUITINGShijiazhuang, China
Contact
-
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
RECRUITINGWuhan, China
Contact
-
XiangYa Hospital CentralSouth University
RECRUITINGChangsha, China
Contact
-
Yibin city second people's Hospital
RECRUITINGYibin, China
Contact
-
Yunnan Cancer Hospital
RECRUITINGKunming, China
Contact
Conditions
Explore the condition pages connected to this study.